Media Room
Second Quarter 2025
Second quarter 2025 results were reviewed by management during a live audio webcast with the financial community on July 31, 2025. The presentation was followed by a Q&A session.
Press releases
September 11, 2025
Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
September 10, 2025
Media Update: ECTRIMS: Sanofi showcases patient focus across multiple sclerosis
September 10, 2025
Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
Contact Our Media Team
You are a journalist and have a question about Sanofi, please contact the Global Media relations team. Please note the contact details are only for journalists.
Publications
Half year 2025 financial report XBRL package
Half Year 2025 Financial Report
Sustainability Statement 2024 (ESG Report)
Registration Document 2024 (in French)